Symposium
Individualised risk reduction strategies for patients with COPD
Translational
Aims : To provide an introduction to the clinically important inflammatory phenotypes of COPD, show that the blood eosinophil count is a valid biomarker of risk and risk reduction with inhaled steroids, review the recent findings of studies on inhaled steroid add-on in cohorts that were stratified by baseline blood eosinophil count and detail the factors that associate with a positive response to macrolides.
Chairs
I. Pavord
Oxford (Oxfordshire)
(United Kingdom)
10:45
Inflammatory phenotypes of COPD
P. Gibson(Newcastle, Australia)
COI
1
1939
11:15
The blood eosinophil count as a biomarker in COPD
M. Bafadhel(London, United Kingdom)
COI
2
1940
11:45
The eNose as a predictor of disease severity and treatment response
P. Sterk(Koudekerk aan den Rijn, Netherlands)
COI
3
1941
12:15
Macrolides for COPD: factors associated with treatment success
M. Han(Ann Arbor, United States)
COI
4
1942
. . .